Recruiting
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors - CA111-001
Mis à jour: 4 janvier, 2024 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Recruiting
Inclusion Criteria: - Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction, castration-resistant prostate cancer (CRPC), ovarian, squamous cell carcinoma of the head and neck (SCCHN), bladder, melanoma, mesothelioma, triple negative breast cancer (TNBC), and soft tissue sarcoma, except for participants with tumors with central nervous system (CNS) metastases as the only site of active disease - Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma) - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Adequate organ function Exclusion Criteria: - Prior organ or tissue allograft - Leptomeningeal metastases - Untreated CNS metastases - Serious or uncontrolled medical disorders Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
